Trials / Completed
CompletedNCT02731352
Study of Apatinib in Patients With Differentiated Thyroid Cancer
Study of Apatinib in Patients With Local Advanced/Metastatic Iodine-131（131I）-Refractory/Resistant Differentiated Thyroid Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Peking Union Medical College Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy and safety of apatinib in locally advanced/metastatic radioactive iodine-refractory/resistant differentiated thyroid cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apatinib | Apatinib Mesylate Tablets 750 mg q.d p.o. in 1-10 cases of differentiated thyroid cancer subjects. |
| DRUG | Apatinib | Apatinib Mesylate Tablets 500 mg q.d. p.o. in 11-20 cases of differentiated thyroid cancer subjects. |
Timeline
- Start date
- 2016-03-11
- Primary completion
- 2020-02-27
- Completion
- 2021-02-28
- First posted
- 2016-04-07
- Last updated
- 2022-01-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02731352. Inclusion in this directory is not an endorsement.